Henry Schein's Stellar Q2 2026 Performance: Plenty of Reasons to Keep Smiling

Well, isn't this a pleasant surprise? Just when you might have been looking for some good news in the market, Henry Schein (headquartered right there in Melville, N.Y.) has delivered, giving us all a fresh reason to smile. Their second-quarter 2026 financial results, announced on August 4, 2026, were, frankly, pretty stellar and have certainly sparked a lot of positive chatter.

Let's dive into the numbers, shall we? Because frankly, they're rather good. The company reported a robust $3.5 billion in total net sales for Q2 2026. That's a healthy 6.7% jump compared to the same period last year, with internal local currency sales growth at a very respectable 4.6%. When it comes to earnings per share, the picture is equally bright. GAAP diluted EPS climbed to $0.82, up from $0.70 in Q2 2025. And for non-GAAP diluted EPS? That came in at $1.27, handily beating the consensus estimate of $1.24 by a solid three cents, and significantly higher than the $1.10 from the previous year.

It wasn't just about EPS, though. Net income saw a nice bump too, rising from $86 million in Q2 2025 to $94 million this quarter. On an adjusted basis, we're talking about an increase from $135 million to $145 million. And if you're keeping an eye on the company's financial health, operating cash flow more than doubled – yes, doubled! – from $120 million to an impressive $242 million. Adjusted EBITDA also showcased strong growth, hitting $288 million, which is a 12.7% increase year-over-year. What's particularly encouraging is that all business segments contributed to this growth. Global Technology sales increased by 8.2%, Global Medical Distribution sales rose by 4.0%, and Global Value-Added Services sales were up by 5.1%.

With such a strong performance under their belt, it’s no wonder that Fred Lowry, the Chief Executive Officer, and Ron South, the Senior Vice President and Chief Financial Officer, felt confident enough to raise the guidance for the full year 2026. The revised non-GAAP diluted EPS guidance now stands between $5.29 and $5.39. They're also projecting mid to high-single-digit adjusted EBITDA growth and overall sales growth of 4.5% to 5.5% for the full year. It's important to note, this positive outlook assumes no further remeasurement gains, keeping the projections grounded.

And the good news doesn't stop there! Looking further ahead, the company anticipates that its value creation initiatives will fuel double-digit earnings growth into 2027. In fact, current expectations suggest Henry Schein's earnings could grow by 10.82% next year, potentially reaching $5.94 per share from an estimated $5.36. As a FORTUNE 500 Company and a member of the S&P 500® index, operating in 34 countries, Henry Schein's continued strength is a significant indicator of health in the broader healthcare sector. For those interested in hearing more directly from the source, Henry Schein is scheduled to present at the Baird Global Healthcare Conference in New York City on September 15, 2026, and their Q3 earnings are estimated for Tuesday, November 3, 2026. All in all, Henry Schein truly gives investors a solid reason to keep smiling.